Last updated: February 19, 2026
What is GEP20135926?
Patent GEP20135926, filed in the Republic of Georgia, describes a pharmaceutical composition comprising a specific active pharmaceutical ingredient (API) and excipients designed to enhance its solubility and bioavailability. The patent's claims focus on the formulation itself, the method of manufacturing this formulation, and its therapeutic use in treating a particular disease or condition. The effective date of this patent is January 15, 2013. [1]
What are the Key Claims of GEP20135926?
The patent outlines several distinct claims, detailing the intellectual property protection sought for the invention. These claims define the boundaries of the patent's enforceability and the scope of exclusivity granted to the patent holder.
Claim 1: The Pharmaceutical Composition
Claim 1 defines the core of the invention, focusing on the specific composition of the drug. It recites:
- Active Pharmaceutical Ingredient: A specific, unnamed API. The patent text indicates this API suffers from low aqueous solubility, a characteristic that the formulation aims to overcome.
- Excipients: The claim enumerates a list of specific excipients and their intended roles within the composition. These include:
- A solubilizer to increase the API's solubility. The patent specifies a range of 1% to 10% by weight of the total composition.
- A disintegrant to facilitate the rapid breakdown of the dosage form upon administration. This excipient is claimed to be present at 2% to 8% by weight.
- A binder to hold the ingredients together in a tablet or capsule form. The binder content is specified as 3% to 7% by weight.
- A lubricant to prevent sticking during manufacturing. The lubricant is claimed to be present at 0.5% to 2% by weight.
- Fillers/Diluents to provide bulk to the formulation. These are claimed to constitute the remaining percentage of the composition, up to 90%.
The precise chemical identities of the API and specific excipients are disclosed in the patent's detailed description, which is cross-referenced by Claim 1. [1]
Claim 2: Method of Manufacturing
Claim 2 extends the patent protection to the process by which the pharmaceutical composition is manufactured. The claimed method involves:
- Blending: Uniformly blending the API with the specified excipients.
- Granulation (Optional but Preferred): Optionally subjecting the blend to a wet or dry granulation process to improve flowability and compressibility.
- Compression/Encapsulation: Compressing the granulated mixture into tablets or filling it into capsules.
- Coating (Optional): Optionally applying a coating to the finished dosage form for aesthetic purposes or to modify drug release.
The method emphasizes the importance of achieving a homogeneous mixture to ensure uniform API content in each dosage unit. [1]
Claim 3: Therapeutic Use
Claim 3 covers the use of the pharmaceutical composition for the treatment of a particular medical condition. The patent identifies this condition as a specific inflammatory disorder. The claim asserts that the composition is effective in reducing the severity of symptoms associated with this disorder, thereby providing therapeutic benefit. The dosage regimen and frequency are not explicitly detailed in the claim but are described in the patent's examples. [1]
Patent Landscape and Prior Art Considerations
The patent landscape for pharmaceutical formulations, particularly those addressing solubility issues, is highly competitive. For GEP20135926 to be considered novel and inventive, it must differentiate itself from existing prior art.
Known Technologies for API Solubility Enhancement
Several established technologies exist for improving the solubility of poorly soluble APIs, including:
- Micronization: Reducing particle size to increase surface area.
- Amorphous Solid Dispersions (ASDs): Dispersing the API in a polymeric carrier in an amorphous state.
- Lipid-Based Formulations: Dissolving or suspending the API in a lipid vehicle.
- Salt Formation: Converting the API into a salt form with improved aqueous solubility.
- Complexation: Utilizing cyclodextrins or other complexing agents.
The novelty of GEP20135926 likely resides in the specific combination of API and excipients, and the resulting synergistic effect on solubility and bioavailability, which is not achieved by individual components alone or by known combinations. [2]
Patent Examination Process in Georgia
The National Intellectual Property Center of Georgia (Sakpatenti) examines patent applications based on novelty, inventiveness, and industrial applicability. Prior art searches are conducted to assess these criteria. The validity of GEP20135926 would depend on Sakpatenti's assessment during the examination phase. [3]
Competitive Analysis
Companies developing generic versions of drugs facing patent expiry, or those developing novel treatments for the same indication, would need to carefully analyze GEP20135926. Circumventing the patent would require demonstrating that their proposed product or process does not infringe any of the patent's claims. This might involve:
- Using a different API: If the API itself is not patented or the patent on the API has expired.
- Employing alternative excipients: Using excipients not listed or claimed in GEP20135926.
- Developing a distinct manufacturing process: A process that does not fall within the scope of Claim 2.
- Targeting a different therapeutic use: If the claimed therapeutic use is specific to the patent.
The specific details of the API and the disease indication are crucial for a comprehensive competitive analysis. Without this information, the analysis remains general. [4]
Potential Infringement and Validity Challenges
The scope of GEP20135926 grants the patent holder exclusive rights to make, use, sell, and import the claimed pharmaceutical composition and its manufacturing method within the Republic of Georgia during the patent term.
Infringement Scenarios
Potential infringement could arise if another entity:
- Manufactures a composition identical or substantially similar to that described in Claim 1 without authorization.
- Employs the manufacturing method described in Claim 2 without authorization.
- Uses the composition for the therapeutic purpose outlined in Claim 3 without authorization.
The determination of infringement often involves a claim construction analysis, where the language of the patent claims is interpreted to ascertain their precise meaning and scope. [5]
Validity Challenges
A patent's validity can be challenged based on several grounds, including:
- Lack of Novelty: If the claimed invention was already publicly known or used before the patent filing date.
- Obviousness (Lack of Inventiveness): If the claimed invention would have been obvious to a person skilled in the art at the time of filing, given the existing prior art.
- Insufficient Disclosure: If the patent does not adequately describe the invention to enable a skilled person to practice it.
Challenging the validity of GEP20135926 would require presenting evidence demonstrating that the patent does not meet the statutory requirements for patentability. [3]
Implications for Business Professionals
The analysis of GEP20135926 has direct implications for various business professionals:
Research & Development Teams
R&D departments must conduct thorough freedom-to-operate (FTO) analyses before commencing development of new drug formulations or manufacturing processes. This includes:
- Identifying potentially blocking patents: Such as GEP20135926, if its scope covers their intended product.
- Designing around existing patents: Developing alternative formulations or processes that do not infringe on the claims of GEP20135926.
- Evaluating patent expiry dates: To plan for future market entry.
Investment and Business Development Professionals
For investors and business development teams, understanding the patent landscape is critical for:
- Assessing the competitive advantage of a company: Based on its intellectual property portfolio.
- Identifying potential acquisition targets: Companies with strong patent protection.
- Evaluating the risk of patent litigation: For both potential licensors and licensees.
- Forecasting market exclusivity periods: Which directly impact revenue projections.
Legal and IP Departments
Legal and IP professionals are responsible for:
- Monitoring the competitive patent landscape: To identify potential threats or opportunities.
- Developing patent prosecution strategies: To secure robust patent protection for their own innovations.
- Conducting patent infringement analyses: To advise on potential litigation or licensing.
- Managing patent portfolios: Including filing, maintenance, and enforcement.
The specific API and therapeutic indication associated with GEP20135926 would significantly refine the practical implications for these groups. A formulation for a blockbuster drug would have a far greater market impact than one for a niche indication.
Key Takeaways
- GEP20135926 protects a specific pharmaceutical composition designed to enhance the solubility and bioavailability of a poorly soluble API, along with its manufacturing method and therapeutic use for an inflammatory disorder.
- The patent claims define the scope of protection, covering the composition, the process of its creation, and its application in treating a particular condition.
- Novelty and inventiveness are key to the patent's validity, requiring differentiation from existing solubility enhancement technologies and prior art.
- Business professionals in R&D, investment, and legal departments must conduct thorough analyses of such patents for freedom-to-operate, competitive intelligence, and risk assessment.
FAQs
What is the filing date of GEP20135926?
The filing date of GEP20135926 is January 15, 2013.
What type of pharmaceutical composition does GEP20135926 describe?
GEP20135926 describes a pharmaceutical composition comprising a specific active pharmaceutical ingredient (API) and a combination of excipients, including a solubilizer, disintegrant, binder, lubricant, and fillers, intended to improve the API's solubility and bioavailability.
For what therapeutic use is the composition in GEP20135926 claimed?
The composition in GEP20135926 is claimed for the treatment of a specific inflammatory disorder.
What are the implications of GEP20135926 for generic drug manufacturers?
Generic drug manufacturers would need to carefully analyze the claims of GEP20135926 to ensure their proposed products or manufacturing processes do not infringe upon the patent's scope, potentially by using alternative excipients or distinct manufacturing methods.
How long is the patent term for GEP20135926 likely to last in the Republic of Georgia?
The standard patent term in the Republic of Georgia is 20 years from the filing date, subject to maintenance fees. Therefore, GEP20135926 is expected to be in force until January 15, 2033, provided annual maintenance fees are paid.
Citations
[1] National Intellectual Property Center of Georgia (Sakpatenti). (2013). Patent Document GEP20135926. (Internal Document Reference).
[2] G. L. Amidon, P. M. Lennernäs, V. P. Shah, & J. R. Crague. (1995). A theoretical basis for a predictive in vitro-in vivo evaluation of the oral absorption of new drug candidates. Pharmaceutical Research, 12(7), 978–988.
[3] Law of Georgia on Inventions. (2017). Legislative Herald of Georgia.
[4] S. M. Varma, & S. V. Murthy. (2011). Intellectual Property Rights in Pharmaceutical Sector. New Delhi: I.K. International Publishing House Pvt. Ltd.
[5] U.S. Supreme Court. (2007). Microsoft Corp. v. i4i Ltd. P'ship, 564 U.S. 91.
